Kodiak Sciences Eye Drug Meets Phase 3 Goals, Matching Competitor Regeneron

Key Facts

Kodiak Sciences announced positive data from its Phase 3 DAYBREAK study for its eye treatments Zenkuda and tabirafusp-ted. Benzinga reported that the study results showed the drug's efficacy is on par with competitor Regeneron's medicine, as the company seeks to establish clinical non-inferiority to support regulatory approval.

KOD closed at $32.35 on September 25, 2026, with the stock trading between a day low of $31 and a high of $33.71 during that session. These clinical findings represent a major milestone for the biotech firm as it aims to secure market share against established treatments in the eye care space.